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Abstract
The standard first-line antiretroviral (ART) regimen in Malawi for both adults and children is a fixed-dose combina-
tion tablet containing stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). This regimen has been shown to
yield satisfactory virologic and immunologic outcomes in children. Published studies have described insights into
discontinuation of first-line regimen and toxicities of ART in adults, but similar studies in paediatric populations are
lacking.
A retrospective cohort study was undertaken to assess reasons for discontinuation of the standard first-line ART
regimen (d4T/3TC/NVP) in a paediatric population. In total, 1434 patients met eligibility criteria and were included.
The cohort had mean and median age at ART initiation of 4.7 years and 2.9 years, respectively (range: 0.1 months-
18.7 years). The gender distribution was 47% female and 53% male. Median follow-up time on ART was 1.8 years
(range: 2 weeks-3.9 years). A majority (96.2%) of patients were on the standard first-line ART regimen, while 3.8%
(54) were on a different regimen. Twenty-eight patients (2.0%) were on an alternative first-line regimen due to toxi-
cities, 22 patients (1.5%) were on a second-line regimen due to ART failure, and four patients (0.3%) were on a
non-standard regimen for other clinical reasons.
Of the 28 patients who experienced toxicities requiring ART regimen change, 60.7% (17) were caused by NVP,
39.3% (11) by d4T, and none by 3TC. The median time from first-line ART initiation to alternative first-line ART was
two months (range: 10 days-28.1 months); 60.7% of patients on alternative first-line ART were male. Average time
on ART until switch to second-line ART regimen was 16.3 months (SD: 9.3 months). The probability of failure after
one year on first-line regimen was 1.6% (95% CI: 0.9-2.6).
There was no compelling evidence in this cohort, representing approximately 10% of all children on ART in Malawi,
to support changing the standard paediatric first-line regimen based on early toxicities or failure. However, experi-
ence from the national adult cohort, longer term follow up of the paediatric cohort in this study, emerging data
on resistance after single-dose NVP containing mother to child transmission antiretroviral prophylaxis, and new
2009 World Health Organization ART recommendations may influence national policy change to a different first-
line regimen.
Findings
The standard first-line antiretroviral (ART) regimen in
Malawi for both adults and children is a fixed-dose
combination tablet containing stavudine (d4T), lamivu-
dine (3TC) and nevirapine (NVP). This regimen is
cheap and convenient, especially where there are limited
affordable alternatives for children in resource-limited
countries like Malawi. NVP is dosed once daily for the
first two weeks of ART using separate d4T/3TC and
NVP tablets, and then increased to twice daily dosing
using d4T/3TC/NVP fixed-dose combination tablets if
well tolerated.
Children are dosed according to locally-developed
weight-band dosing tables using fractions of adult Trio-
mune 30 tablets. This approach has been shown to
result in satisfactory virologic and immunologic benefit
to children [1]. However, there are concerns about NVP
drug levels in children on fractionated adult tablets [2].
There is also evidence that single-dose NVP (sdNVP)-
containing mother to child transmission (MTCT) antire-
troviral (ARV) prophylaxis regimens increase the risk of
resistance and failure of NVP-based ART regimens in
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children [3]. During the time of this study, all children
received split adult Triomune 30 tablets as the paedia-
tric formulation; Triomune Baby was introduced at a
national level in 2009, after our study period. In addi-
tion, there were no provisions for a protease inhibitor-
based first-line regimen for infants with sdNVP MTCT
ARV prophylaxis exposure in the national ART
guidelines.
The national ART programme offers additional ART
regimens when d4T/3TC/NVP is no longer a tolerable
or effective regimen. In the case of adverse drug reac-
tions or toxicities to the first-line regimen, alternative
first-line regimens are available, which replace d4T with
zidovudine (AZT), and NVP with efavirenz (EFZ). In
cases of ART failure, which can be diagnosed clinically,
immunologically or virologically depending on the set-
ting, second-line regimens are available. The adult
second-line regimen is AZT, 3TC, tenofovir and lopina-
vir/ritonavir, while the paediatric second-line regimen is
abacavir, didanosine and lopinavir/ritonavir.
The Malawi Ministry of Health is investigating a
potential change of the national standard first-line regi-
men, in part due to concerns about the high prevalence
of d4T-related toxicities, particularly peripheral neuro-
pathy in adults, in line with guidelines released World
Health Organization (WHO) in late 2009 on preferred
first-line ART regimens [4]. Published studies have
described insights into discontinuation of first-line regi-
men and toxicities to ART in adults [5], but similar stu-
dies in paediatric populations are lacking [6,7].
An analysis of retrospectively collected cohort data
was undertaken to assess the reasons for discontinuation
of standard first-line ART in a cohort of children at the
Baylor College of Medicine-Abbott Fund Children’s
Clinical Centre of Excellence-Malawi as a step towards
assisting the Ministry of Health in making an informed
decision based on locally available data. Our paediatric
HIV care programme operates from the capital city,
Lilongwe, and has enrolled more than 4500 infants and
children since its inception in 2004. As of July 2009,
there was an active caseload of 2330 HIV-infected and
exposed patients, 1444 of whom were on ART. By the
end of 2008, our patient population represented
approximately 10% of all children ever initiated on ART
in Malawi [8].
We investigated the discontinuation of standard first-
line ART as our primary outcome. Toxicities were
defined as adverse events reported after ART initiation,
which were confirmed clinically or with laboratory tests
when available. ART failure was identified clinically,
immunologically and virologically using national ART
and WHO guidelines.
Eligibility criteria for the study were patients aged 19
years or younger, with at least two clinic visits, who
were ART-naïve at the time of standard first-line initia-
tion (excluding MTCT ARV prophylaxis exposure), and
who had enrolled between November 2004 and October
2008, either at our clinic or at its predecessor clinic at
Kamuzu Central Hospital in Lilongwe. All patients had
records in our electronic medical record (EMR) which
were de-identified and subsequently reviewed. Patients
on an ART regimen other than the standard first-line
regimen were identified through the EMR and con-
firmed by cross checking with our paper-based national
ART registers. It is not possible to reliably query our
EMR for patients who had ART toxicities or first-line
failure that did not result in an ART regimen change.
For this reason, we used discontinuation of the first-line
regimen as a proxy for toxicity and failure. Data were
analyzed using STATA version 9 (STATA Corporation,
College Station, Texas, USA).
A total of 1434 patients met eligibility criteria and
were included in this review. Fewer than 15 patients had
stopped ART for poor adherence or social concerns at
the time of the analysis and were not included in this
review as they were expected to resume the standard
first-line regimen at the time of re-initiation. The cohort
had mean and median ages at ART initiation of 4.7
years and 2.9 years, respectively, with a range of 0.1
months to 18.7 years. The gender distribution was 47%
female and 53% male. The median follow-up time on
ART was 1.8 years with a range of two weeks to 3.9
years.
A majority of patients (96.2%) were on the standard
first-line ART regimen, while 3.8% (54) were on a differ-
ent regimen: 28 patients (2.0%) were on an alternative
first-line regimen due to toxicities, 22 patients (1.5%)
were on a second-line regimen due to failure, and four
patients (0.3%) were on a non-standard regimen for
other clinical reasons. Of the 28 patients with toxicities
requiring ART regimen change, 60.7% (17) were related
to NVP, 39.3% (11) were related to d4T, and none were
related to 3TC, as shown in Table 1.
The median time to substitution of alternative first-
line ART was two months, with a range of 10 days
to 28.1 months. Of the patients on alternative first-line
ART, 60.7% were male. Average time on ART until
switch to second-line ART regimen was 16.3 months
(SD: 9.3 months). The probability of failure after
one year on the first-line regimen was 1.6% (95%
CI: 0.9-2.6).
This retrospective cohort review shows that the Mala-
wian standard first-line ART regimen of d4T/3TC/NVP
fixed-dose combination resulted in limited early toxici-
ties requiring ART regimen change in this paediatric
population. It also shows that early first-line ART failure
requiring switch to second-line ART was not commonly
diagnosed in our cohort.
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There are limitations of this retrospective review that
should be mentioned. First, due to the study design,
there are certainly patients in this large cohort with
toxicities that were not captured, either because the
patients’ adverse reactions were not severe enough to
warrant a regimen change or because they were never
diagnosed. This is of particular concern with respect to
lipodystrophy. In addition, as per national guidelines,
patients did not get routine laboratory monitoring for
ART toxicities, such as liver function tests, pancreatic
enzymes or other chemistry investigations. This
approach of no routine laboratory monitoring has been
validated as cost effective and safe in African settings,
but likely results in under-diagnosis of sub-clinical
laboratory toxicities [9].
Another limitation of our study design is that it only
captured patients who had been switched to second-line
ART for confirmed failure. Our patients do get biannual
CD4 testing, but routine viral load testing is not done at
our clinic, or anywhere in the Malawi national ART
programme. As a result, first-line failure is almost cer-
tainly under-represented here as patients have to present
with later-onset clinical or immunologic failure before
viral load tests are ordered.
A final limitation is that the median time on ART was
relatively short at only 1.8 years, as the national ART
programme only began including ART for children in
the public health facilities in 2004. Many metabolic
complications from longer term d4T treatment, includ-
ing peripheral neuropathy, lactic acidosis and lipodystro-
phy, might not have presented within this limited
timeframe. A similar analysis will need to be repeated in
the future to evaluate metabolic complications after
patients have been on ART for longer periods.
In conclusion, there was no compelling evidence in
this cohort, representing approximately 10% of all chil-
dren on ART in Malawi, to support changing the stan-
dard Malawian first-line regimen of d4T/3TC/NVP
based on early toxicities or failure. However, experience
from the adult cohort, longer term follow up of the pae-
diatric cohort in this study, emerging data on NVP
resistance after sdNVP-containing MTCT ARV prophy-
laxis, and new 2009 WHO ART recommendations may
influence national policy change to a different first-line
regimen.
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Table 1 Reasons for discontinuation of standard first-line ART regimen
Reason for discontinuation of
standard first-line ART (d4T/3TC/NVP) a
Number of patients (male/female) Proportion of
total cohort of 1434 patients (%)
Toxicity 28 (17/11) 1.95%
• Nevirapine - rash (unknown WHO grade) 1 (0/1) 0.07%
• Nevirapine - rash (WHO grade II) 5 (3/2) 0.35%
• Nevirapine - rash (WHO grade III) 4 (2/2) 0.28%
• Nevirapine - Stevens-Johnson syndrome (WHO grade IV) b 5 (4/1) 0.35%
• Nevirapine - hepatitis (WHO grade IV) c 2 (2/0) 0.14%
• Nevirapine - total 17 (11/6) 1.19%
• Stavudine - pancreatitis (WHO grade III) 3 (2/1) 0.21%
• Stavudine - pancreatitis (WHO grade IV) 2 (1/1) 0.14%
• Stavudine - lactic acidosis (unknown WHO grade) 1 (1/0) 0.07%
• Stavudine - lactic acidosis (WHO grade III) 3(1/2) 0.21%
• Stavudine - peripheral neuropathy (unknown WHO grade) 1 (0/1) 0.07%
• Stavudine toxicity - peripheral neuropathy (WHO grade III) 1 (1/0) 0.07%
• Stavudine - total 11 (6/5) 0.76%
First-line failure d 22 (16/6) 1.53%
Other e 4 (3/1) 0.28%
aToxicity grading per 2006 WHO guidelines (I-mild, II-moderate, III-severe, IV-severe, potentially life-threatening).
bOne patient died from drug-induced SJS.
cOne patient had a negative Hepatitis B surface antigen test documented. Serologies for other viral hepatitides are not available in Malawi. Neither patient was
on concurrent TB treatment.
dAll patients in our cohort had confirmed virologic failure on first-line ART.
eFour Kaposi’s sarcoma patients had been placed on a protease inhibitor-based regimen for possible antiangiogenic effects.
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